allergy asthma
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: General inclusion criteria: - Written informed consent - Male and female persons, aged >= 18 years and 16 mg/ml - specific IgE >= 0.7 kU/l for tree or grass pollen and/or house dust mite (HDM) - positive skin prick test response ( wheal > 5 mm) for tree or grass pollen and/or HDM - total IgE >30 70% (short-acting β2-agonists if needed) - History of episodic symptoms of wheezing, breathlessness, cough or chest tightness (>12 months) - PC20 of histamine 5 mm) for tree or grass pollen and/or HDM - specific IgE >= 0.7 kU/l for tree or grass pollen and/or house dust mite (HDM) - total IgE >30 16 mg/ml - Specific IgE
Exclusion criteria
Exclusion criteria: age = 0.7 kU/l for animals to which the patients has daily contact with Immunotherapy for the last 5 years Anatomical abnormalities of the nose Contraindications for immunotherapy according to international guidelines anti-IgE treatment previously systemic steroids or suffered exacerbations in the last year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-10 producing B cells in PBMC IL-4 producing T cells (Th2 cells) in reaction to relevant allergens | — |
Secondary
| Measure | Time frame |
|---|---|
| Total IgE and allergen-specific IgE, IgG1, IgG2a, IgG4, IgA in plasma and nose washings. Affinity of allergen-specific IgE molecules TNFalpha and IL-10 in plasma and nose washings. Molecular profiling of B cell populations with ATACseq | — |
Countries
Netherlands
Outcome results
None listed